中枢神经系统治疗市场－全球产业规模、份额、趋势、机会及预测（依药物类别、适应症、给药途径、最终用户、分销管道、地区和竞争格局划分），2021-2031年

全球中枢神经系统治疗市场预计将从2025年的1,152.1亿美元成长至2031年的1,824.2亿美元，复合年增长率（CAGR）为7.96%。这些治疗药物旨在治疗影响大脑和脊髓的神经和精神疾病，例如阿兹海默症和忧郁症。推动这一增长的关键因素包括全球人口快速老化及其导致的神经退化性疾病的增加，以及全球对精神健康问题的日益关注，这都促进了对更有效药物治疗的需求。

然而，由于开发能够穿透血脑障壁的药物涉及极其复杂的科学原理，该行业面临许多重大挑战。血脑障壁往往导致临床试验的高失败率，而这种复杂性也会增加研发成本和延长研发週期，从而限制市场成长。为了说明克服这些挑战所需的巨额投资，欧洲製药工业协会联合会（EFPIA）估计，到2024年，以研发为基础的製药业将在欧洲的研发领域投入550亿欧元。

市场驱动因素

全球神经系统和精神疾病盛行率的不断上升是推动全球中枢神经系统治疗市场成长的主要因素。随着预期寿命的延长，神经退化性疾病的累积风险也在增加，导致需要长期药物治疗的患者群体不断扩大。精神疾病的广泛发病进一步加剧了这一趋势，因为精神疾病需要优先获得治疗。健康指标与评估研究所 (IHME) 于 2024 年 3 月在《刺胳针神经病学》杂誌上发表的一项研究凸显了这场健康危机的严重性。该研究估计，全球有超过 34 亿人患有神经系统疾病，使其成为全球疾病和残疾的主要原因之一。

同时，强大的临床开发平臺和不断增长的神经科学研发投入正在推动市场发展。製药公司正积极寻求策略併购和联盟，以获取新的药物作用机制，尤其是在思觉失调症和阿兹海默症复杂疾病领域，从而加速治疗药物的商业化进程，并克服血脑障壁渗透性等障碍。例如，2023年12月，百时美施贵宝同意以140亿美元的股票收购Karuna Therapeutics，以增强其精神科产品以金额为准。此外，阿兹海默症协会预测，到2024年，美国阿兹海默症和其他失智症患者的医疗总费用将达到3,600亿美元，凸显了有效治疗方法的巨大商业性潜力。

市场挑战

全球中枢神经系统治疗药物市场面临的主要限制因素是开发能够有效穿过血脑障壁的药物的科学难度。这种生物屏障会选择性地阻止许多潜在疗法到达大脑靶区，导致极高的失败率，因为即使临床前数据积极的化合物，在临床试验中也往往无法证明其安全性和有效性。因此，企业不得不接受漫长的研发週期，并承担神经系统研究倡议相关的高昂财务风险。

应对这些风险所需的大量资源限制了参与企业数量，并压缩了成功药物的利润空间，这不仅为小规模的营业单位设置了障碍，还延缓了新治疗方法的上市。生物技术与创新组织（BIO）的数据凸显了这些挑战的严峻性。该组织报告称，到2024年，新疗法候选药物的临床开发成功率约为6.7%。与成功率较高的治疗领域相比，这种较低的核准可能性往往会抑制对中枢神经系统（CNS）领域的投资，从而阻碍整体市场扩张。

市场趋势

市场的一个关键转变是神经退化性疾病治疗领域向缓解疾病生物製药的转型，这使得治疗重点从缓解症状转向阿兹海默症潜在病因的标靶治疗。这一趋势主导由抗淀粉样蛋白单株抗体的商业化所推动，这类抗体能够清除斑块沉积并延缓认知衰退，其发展正在改变收入模式，并刺激对诊断和输注基础设施的投资。鑑于这些治疗方法的快速普及，Eisai在2024年11月的新闻稿中宣布，预计其阿兹海默症治疗药物Rekenvi在截至2025年3月的财年全球销售额将达到425亿日圆。

同时，利用人工智慧（AI）识别中枢神经系统（CNS）标靶正在加速发现有前景的候选药物，并降低神经系统药物研发的传统失败率。製药公司正越来越多地与人工智慧专家合作，利用机器学习演算法分析大规模生物数据集，从而实现对药物-标靶相互作用的精准预测，并在临床试验前优化分子结构。例如，Formation Bio在2024年6月的新闻稿中宣布，已获得3.72亿美元的D轮融资，赛诺菲也参与了此次资金筹措，旨在增强其人工智慧驱动的药物发现能力。

目录

第一章概述

第二章调查方法

第三章执行摘要

第四章：客户评价

第五章 全球中枢神经系统药物市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 依药物类别（多发性硬化症药物、抗精神病药物、抗癫痫药物、止痛药/麻醉剂、抗巴金森氏症药物、其他）
  • 依应用领域（神经退化性疾病、精神健康与创伤、神经血管疾病、感染疾病、中枢神经系统癌症、其他）
  • 依给药途径（口服、肠外、其他）
  • 依最终使用者（医院、诊所、诊断检查室等）划分
  • 按分销管道（医院药房、网路药房、零售药房）
  • 按地区
  • 按公司（2025 年）
• 市场地图

6. 北美中枢神经系统治疗市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国家分析
  • 美国
  • 加拿大
  • 墨西哥

7. 欧洲中枢神经系统药物市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

8. 亚太地区中枢神经系统治疗市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

9. 中东和非洲中枢神经系统药物市场展望

• 市场规模及预测
• 市占率及预测
• 中东和非洲：国家分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

第十章：南美洲中枢神经系统药物市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国家分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 司机
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 最新进展

第十三章 全球中枢神经系统治疗市场：SWOT分析

第十四章 波特五力分析

• 产业竞争
• 新进入者的可能性
• 供应商电力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• Pfizer Inc.
• Eli Lilly and Company
• Johnson & Johnson Services, Inc.
• Novartis International AG
• Roche Holding AG
• Bristol-Myers Squibb Company
• Sanofi SA
• GlaxoSmithKline plc
• AbbVie Inc.
• AstraZeneca plc

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global Central Nervous System Therapeutics Market is projected to expand from USD 115.21 billion in 2025 to USD 182.42 billion by 2031, reflecting a CAGR of 7.96%. These therapeutics consist of pharmaceutical interventions aimed at treating neurological and psychiatric conditions affecting the brain and spinal cord, such as Alzheimer's disease and depression. Key factors fueling this growth include rapidly aging global demographics and the resulting increase in neurodegenerative diseases, alongside a rising worldwide awareness of mental health issues that sustains demand for effective pharmacological treatments.

Conversely, the industry faces significant obstacles due to the scientific intricacies involved in developing drugs capable of crossing the blood-brain barrier, a hurdle that frequently contributes to high failure rates in clinical trials. This complexity leads to increased development costs and extended timelines, which can constrain market growth. Highlighting the massive financial resources dedicated to navigating these challenges, the European Federation of Pharmaceutical Industries and Associations estimated that the research-based pharmaceutical industry invested €55 billion in research and development across Europe in 2024.

Market Driver

The rising global prevalence of neurological and psychiatric disorders serves as the primary engine for growth in the Global Central Nervous System Therapeutics Market. As life expectancy rises, the cumulative risk of neurodegenerative conditions increases, creating a larger patient population requiring long-term pharmaceutical management, a trend further amplified by the widespread occurrence of mental health disorders that necessitate prioritized therapeutic access. The magnitude of this health crisis was highlighted by a study published in 'The Lancet Neurology' by the Institute for Health Metrics and Evaluation in March 2024, which estimated that over 3.4 billion people worldwide are affected by neurological conditions, making them the leading cause of global ill health and disability.

Concurrently, the market is boosted by a strong clinical pipeline and increased capital investment in neuroscience research and development. Pharmaceutical companies are actively pursuing strategic mergers and partnerships to acquire novel mechanisms of action, particularly for complex conditions like schizophrenia and Alzheimer's disease, thereby accelerating the commercialization of treatments and addressing barriers such as blood-brain barrier penetration. For instance, Bristol Myers Squibb agreed to acquire Karuna Therapeutics for an equity value of $14 billion in December 2023 to enhance its psychiatry portfolio, while the Alzheimer's Association projected in 2024 that total care payments for Americans with Alzheimer's and other dementias would reach $360 billion, underscoring the immense commercial potential for effective therapies.

Market Challenge

A major constraint on the global central nervous system therapeutics market is the scientific difficulty of creating drugs that can successfully traverse the blood-brain barrier. This biological filter selectively blocks many potential treatments from reaching targeted areas in the brain, resulting in exceptionally high attrition rates during clinical trials where compounds frequently fail to prove safety or efficacy in humans despite favorable preclinical data. Consequently, companies are compelled to lengthen development timelines and accept higher financial risks associated with neurological research initiatives.

The significant resources needed to manage these risks restrict the number of market participants and compress profit margins for successful drugs, creating hurdles for smaller entities and slowing the launch of new therapies. The severity of these challenges is evident in data from the Biotechnology Innovation Organization, which reported in 2024 that the clinical development success rate for new therapeutic candidates was approximately 6.7 percent. This low likelihood of approval tends to deter investment in CNS compared to therapeutic areas with higher success rates, thereby inhibiting the overall expansion of the market.

Market Trends

A pivotal transformation in the market is the shift toward disease-modifying biologics for neurodegenerative disorders, moving the focus from symptomatic relief to targeting underlying pathologies like Alzheimer's disease. This trend is led by the commercialization of anti-amyloid monoclonal antibodies capable of clearing plaque deposits and slowing cognitive decline, a development that is altering revenue models and spurring investment in diagnostic and infusion infrastructure. Reflecting the rapid uptake of these therapies, Eisai Co., Ltd. projected in a November 2024 press release that global revenue for its Alzheimer's treatment, Leqembi, would reach JPY 42.5 billion for the fiscal year ending March 2025.

Simultaneously, the adoption of artificial intelligence for CNS target identification is expediting the discovery of viable drug candidates and addressing historic failure rates in neurological development. Pharmaceutical firms are increasingly collaborating with AI-specialized companies to utilize machine learning algorithms that analyze massive biological datasets, enabling precise prediction of drug-target interactions and optimization of molecular structures prior to clinical testing. Demonstrating the significant capital flowing into this area, Formation Bio announced in a June 2024 press release that it secured $372 million in Series D financing, with participation from Sanofi, to enhance its AI-driven drug development capabilities.

Key Market Players

• Pfizer Inc.
• Eli Lilly and Company
• Johnson & Johnson Services, Inc.
• Novartis International AG
• Roche Holding AG
• Bristol-Myers Squibb Company
• Sanofi S.A.
• GlaxoSmithKline plc
• AbbVie Inc.
• AstraZeneca plc

Report Scope

In this report, the Global Central Nervous System Therapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Central Nervous System Therapeutics Market, By Drug Class

• Multiple Sclerosis
• Antipsychotic
• Antiepileptics
• Analgesics & Anesthetics
• Anti-Parkinson
• Others

Central Nervous System Therapeutics Market, By Application

• Neurodegenerative Diseases
• Mental Health and Trauma
• Neurovascular Diseases
• Infectious Diseases
• CNS Cancer
• Others

Central Nervous System Therapeutics Market, By Route of Administration

• Oral
• Parenteral
• Others

Central Nervous System Therapeutics Market, By End User

• Hospital
• Clinics
• Diagnostic Laboratories
• Others

Central Nervous System Therapeutics Market, By Distribution Channel

• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy

Central Nervous System Therapeutics Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Central Nervous System Therapeutics Market.

Available Customizations:

Global Central Nervous System Therapeutics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Central Nervous System Therapeutics Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Drug Class (Multiple Sclerosis, Antipsychotic, Antiepileptics, Analgesics & Anesthetics, Anti-Parkinson, Others)
  • 5.2.2. By Application (Neurodegenerative Diseases, Mental Health and Trauma, Neurovascular Diseases, Infectious Diseases, CNS Cancer, Others)
  • 5.2.3. By Route of Administration (Oral, Parenteral, Others)
  • 5.2.4. By End User (Hospital, Clinics, Diagnostic Laboratories, Others)
  • 5.2.5. By Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)
  • 5.2.6. By Region
  • 5.2.7. By Company (2025)
• 5.3. Market Map

6. North America Central Nervous System Therapeutics Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Drug Class
  • 6.2.2. By Application
  • 6.2.3. By Route of Administration
  • 6.2.4. By End User
  • 6.2.5. By Distribution Channel
  • 6.2.6. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Central Nervous System Therapeutics Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Drug Class
      • 6.3.1.2.2. By Application
      • 6.3.1.2.3. By Route of Administration
      • 6.3.1.2.4. By End User
      • 6.3.1.2.5. By Distribution Channel
  • 6.3.2. Canada Central Nervous System Therapeutics Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Drug Class
      • 6.3.2.2.2. By Application
      • 6.3.2.2.3. By Route of Administration
      • 6.3.2.2.4. By End User
      • 6.3.2.2.5. By Distribution Channel
  • 6.3.3. Mexico Central Nervous System Therapeutics Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Drug Class
      • 6.3.3.2.2. By Application
      • 6.3.3.2.3. By Route of Administration
      • 6.3.3.2.4. By End User
      • 6.3.3.2.5. By Distribution Channel

7. Europe Central Nervous System Therapeutics Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Drug Class
  • 7.2.2. By Application
  • 7.2.3. By Route of Administration
  • 7.2.4. By End User
  • 7.2.5. By Distribution Channel
  • 7.2.6. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Central Nervous System Therapeutics Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Drug Class
      • 7.3.1.2.2. By Application
      • 7.3.1.2.3. By Route of Administration
      • 7.3.1.2.4. By End User
      • 7.3.1.2.5. By Distribution Channel
  • 7.3.2. France Central Nervous System Therapeutics Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Drug Class
      • 7.3.2.2.2. By Application
      • 7.3.2.2.3. By Route of Administration
      • 7.3.2.2.4. By End User
      • 7.3.2.2.5. By Distribution Channel
  • 7.3.3. United Kingdom Central Nervous System Therapeutics Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Drug Class
      • 7.3.3.2.2. By Application
      • 7.3.3.2.3. By Route of Administration
      • 7.3.3.2.4. By End User
      • 7.3.3.2.5. By Distribution Channel
  • 7.3.4. Italy Central Nervous System Therapeutics Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Drug Class
      • 7.3.4.2.2. By Application
      • 7.3.4.2.3. By Route of Administration
      • 7.3.4.2.4. By End User
      • 7.3.4.2.5. By Distribution Channel
  • 7.3.5. Spain Central Nervous System Therapeutics Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Drug Class
      • 7.3.5.2.2. By Application
      • 7.3.5.2.3. By Route of Administration
      • 7.3.5.2.4. By End User
      • 7.3.5.2.5. By Distribution Channel

8. Asia Pacific Central Nervous System Therapeutics Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Drug Class
  • 8.2.2. By Application
  • 8.2.3. By Route of Administration
  • 8.2.4. By End User
  • 8.2.5. By Distribution Channel
  • 8.2.6. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Central Nervous System Therapeutics Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Drug Class
      • 8.3.1.2.2. By Application
      • 8.3.1.2.3. By Route of Administration
      • 8.3.1.2.4. By End User
      • 8.3.1.2.5. By Distribution Channel
  • 8.3.2. India Central Nervous System Therapeutics Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Drug Class
      • 8.3.2.2.2. By Application
      • 8.3.2.2.3. By Route of Administration
      • 8.3.2.2.4. By End User
      • 8.3.2.2.5. By Distribution Channel
  • 8.3.3. Japan Central Nervous System Therapeutics Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Drug Class
      • 8.3.3.2.2. By Application
      • 8.3.3.2.3. By Route of Administration
      • 8.3.3.2.4. By End User
      • 8.3.3.2.5. By Distribution Channel
  • 8.3.4. South Korea Central Nervous System Therapeutics Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Drug Class
      • 8.3.4.2.2. By Application
      • 8.3.4.2.3. By Route of Administration
      • 8.3.4.2.4. By End User
      • 8.3.4.2.5. By Distribution Channel
  • 8.3.5. Australia Central Nervous System Therapeutics Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Drug Class
      • 8.3.5.2.2. By Application
      • 8.3.5.2.3. By Route of Administration
      • 8.3.5.2.4. By End User
      • 8.3.5.2.5. By Distribution Channel

9. Middle East & Africa Central Nervous System Therapeutics Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Drug Class
  • 9.2.2. By Application
  • 9.2.3. By Route of Administration
  • 9.2.4. By End User
  • 9.2.5. By Distribution Channel
  • 9.2.6. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Central Nervous System Therapeutics Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Drug Class
      • 9.3.1.2.2. By Application
      • 9.3.1.2.3. By Route of Administration
      • 9.3.1.2.4. By End User
      • 9.3.1.2.5. By Distribution Channel
  • 9.3.2. UAE Central Nervous System Therapeutics Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Drug Class
      • 9.3.2.2.2. By Application
      • 9.3.2.2.3. By Route of Administration
      • 9.3.2.2.4. By End User
      • 9.3.2.2.5. By Distribution Channel
  • 9.3.3. South Africa Central Nervous System Therapeutics Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Drug Class
      • 9.3.3.2.2. By Application
      • 9.3.3.2.3. By Route of Administration
      • 9.3.3.2.4. By End User
      • 9.3.3.2.5. By Distribution Channel

10. South America Central Nervous System Therapeutics Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Drug Class
  • 10.2.2. By Application
  • 10.2.3. By Route of Administration
  • 10.2.4. By End User
  • 10.2.5. By Distribution Channel
  • 10.2.6. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Central Nervous System Therapeutics Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Drug Class
      • 10.3.1.2.2. By Application
      • 10.3.1.2.3. By Route of Administration
      • 10.3.1.2.4. By End User
      • 10.3.1.2.5. By Distribution Channel
  • 10.3.2. Colombia Central Nervous System Therapeutics Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Drug Class
      • 10.3.2.2.2. By Application
      • 10.3.2.2.3. By Route of Administration
      • 10.3.2.2.4. By End User
      • 10.3.2.2.5. By Distribution Channel
  • 10.3.3. Argentina Central Nervous System Therapeutics Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Drug Class
      • 10.3.3.2.2. By Application
      • 10.3.3.2.3. By Route of Administration
      • 10.3.3.2.4. By End User
      • 10.3.3.2.5. By Distribution Channel

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Central Nervous System Therapeutics Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Pfizer Inc.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Eli Lilly and Company
• 15.3. Johnson & Johnson Services, Inc.
• 15.4. Novartis International AG
• 15.5. Roche Holding AG
• 15.6. Bristol-Myers Squibb Company
• 15.7. Sanofi S.A.
• 15.8. GlaxoSmithKline plc
• 15.9. AbbVie Inc.
• 15.10. AstraZeneca plc

16. Strategic Recommendations

17. About Us & Disclaimer